Thermo Fisher Scientific Inc

In Q3, billionaire investor Leon Cooperman’s top five holdings were Fiserv, Alphabet, United Continental, Chimera Investment, and Cigna.

In fiscal 2018 and fiscal 2019, Thermo Fisher Scientific (TMO) is expected to generate revenue of $24.08 billion and $25.19 billion, respectively, compared with revenue of $20.92 billion in fiscal 2017.

In this series, we’ll explore Thermo Fisher’s financials and valuation, and analysts’ views on its stock.

In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.

Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.

For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.

Thermo Fisher Scientific (TMO) reported its third-quarter results today. It surpassed analysts’ estimates for EPS and revenue.

Johnson & Johnson’s (JNJ) Medical Devices segment generated net revenues of $6.6 billion in the third quarter, reflecting ~0.2% YoY growth.

The Life Sciences Solutions segment, including reagents, instruments, and consumables, contributes ~25% of Thermo Fisher’s total revenues.

Thermo Fisher Scientific (TMO), a leading life sciences company, is scheduled to release its third-quarter earnings on October 24.

Edwards Lifesciences is expected to register third-quarter adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise.

Wall Street expects Edwards Lifesciences to register sales of $0.93 billion in the third quarter, representing a YoY (year-over-year) rise of 10.8%.

Abbott Laboratories (ABT) is slated to announce its third-quarter earnings results on October 17.

In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.

The mean rating for ResMed (RMD) stock is 2.6, and its target price is $104.69.

In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”

In the last three months, Agilent Technologies (A) stock has risen from $61.14 on June 27, 2018, to $70.33 in September 2018.

Abbott stock has been gaining momentum recently, and its valuation has improved.

Quest Diagnostics’ (DGX) diagnostic information services (or DIS) business accounts for more than 95% of the company’s total revenues.

Quest Diagnostics generated revenues of $1.92 billion in the second quarter of 2018 as compared with $1.86 billion in the second quarter of 2017.

So far in 2018, Thermo Fisher Scientific (TMO) stock has generated double-digit returns for investors.

Thermo Fisher Scientific (TMO) operates in four business segments.

As of September 18, ten of the 19 analysts that cover HOLX stock gave the company a “buy” or “strong buy” recommendation.

Currently, HOLX stock is trading lower than its 50-day moving average of $39.80 but higher than its 200-day moving average of $39.16.

Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company would acquire the Advanced Bioprocessing Business from Becton Dickinson (BDX).

Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.

Thermo Fisher Scientific currently trades at a forward PE multiple of ~19.9x.

The company has delivered a robust financial performance in recent quarters. However, the stock has been on a bearish trend during the recent period.

Illumina (ILMN) reached a 52-week high of $357.93 per share on August 31.

In July, Roche received the CE Mark for its Accu-Chek Solo micropump system.

Wall Street analysts estimate Haemonetics’s (HAE) Q1 2019 revenues to increase ~4.3% to $219.9 million as compared to $210.9 million during Q1 2018.

In the second quarter, Boston Scientific’s adjusted EPS grew 28% YoY (year-over-year) to $0.41, exceeding its guidance of $0.33–$0.35.

Wall Street analysts expect Thermo Fisher’s (TMO) revenues to reflect 18.1% growth to $5.9 billion during the second quarter.

As of April 25 and according to a recent Reuters survey of 16 research firms, TMO stock is rated a “strong buy” by eight analysts.

On April 25, Thermo Fisher Scientific (TMO) announced its results for 1Q18. Its revenues rose 23% YoY to $5.9 billion.

On March 28, 2018, Hologic (HOLX) stock ended trading at a closing price of $37.39.

On March 28, 2018, Becton, Dickinson and Company (BDX) ended trading at a closing price of $212.43.

On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory.

On March 14, 2018, Thermo Fisher Scientific (TMO) closed at $213.46 per share.

On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of its new high-pressure Ion Chromatography System.

Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, and consumables, diagnostics and research software, and services.

On March 14, 2018, Thermo Fisher Scientific (TMO) stock started trading ex-dividend.

As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x.

On February 7, 2018, Stryker (SYK) announced a quarterly dividend of $0.47 per share.

Tax reform and Medtronic’s 3Q18 results The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to […]

Abbott Laboratories (ABT) has recorded strong growth recently, registering stellar performance.

Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.

Becton Dickinson (BDX) announced its fiscal 2018 guidance, which includes the company’s recently acquired Bard business, during the company’s 1Q18 earnings release.

BD posted 1Q18 results as a standalone company and didn’t include Bard sales in 1Q18.

On February 6, 2018, BD released its 1Q18 earnings results, which came in ahead of expectations.

Abbott’s plan will be to focus on organic growth over the next year and going forward, after a slew of major acquisitions and strategic divestitures.

On January 23, 2018, Thermo Fisher Scientific (TMO) traded at its 52-week high of $217.22. However, it closed at $214.55.

Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.

In June 2017, Accelerate Diagnostics (AXDX) raised net proceeds of $83.2 million from a public offering of 2.8 million shares of common stock.

The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.

Accelerate Diagnostics (AXDX) currently competes with companies with automated microbiological testing products on the market like Becton Dickinson (BDX), bioMerieux, Danaher (DHR), Bruker (BRKR), Luminex (LMNX), and T2 Biosystems (TTOO).

Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” rating.

Stryker (SYK) offers products across its three business segments: Orthopedics, MedSurg, and Neurotechnology and Spine. The company reported strong performance across all of its business segments in fiscal 3Q17.

Earnings results Baxter International (BAX) is expected to announce its 4Q17 and fiscal 2017 earnings results on or around January 30, 2018. The company announced stellar 3Q17 earnings results on October 25, 2017. Year-over-year, Baxter International expects to report 4Q17 sales growth of 4%–5% and constant-currency sales growth of ~2%. However, the company’s operational sales growth, expected […]

Analysts’ recommendations Baxter International (BAX), one of the United States’ leading medical technology companies, offers renal and hospital solutions to healthcare providers. The company has witnessed strong growth momentum recently, and Wall Street has grown increasingly bullish on the company’s growth prospects. In this article, we’ll look at analysts’ recent recommendations, ratings, and price targets for BAX stock. […]

On December 28, Becton, Dickinson and Company (BDX), or BD, closed trading on the day at $214.32 per share. Currently, BD stock’s 50-day moving average stands at $221.22.

TMO stock reported its 52-week high of $201.20 on October 26, 2017, when the company released its 3Q17 earnings results.

On December 4, 2017, Leerink Swann reaffirmed its “outperform” rating on Thermo Fisher Scientific (TMO). It decreased its target price on TMO stock from $216.00 per share to $200.00 per share.

On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.

On December 4, 2017, Thermo Fisher Scientific (TMO) completed the acquisition of some assets from EPTEK Technology and related entities that have offices in mainland China and Taiwan.

On December 7, 2017, Thermo Fisher Scientific (TMO) announced that its Oncomine Dx Target Test had been proposed for coverage by the CMS (Centers for Medicare & Medicaid Services).

Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.

In December 2017, Thermo Fisher Scientific (TMO) expanded its partnership with Genome Diagnostics (or GenDx), a Netherlands-based firm offering molecular diagnostics solutions.

On December 7, 2017, Thermo Fisher Scientific announced the launch of a new targeted NGS (next-generation sequencing) research panel.

Overview Stryker (SYK), a leading medical technology company in the United States, has a wide portfolio of products across its three business segments: Orthopaedics, MedSurg, and NeuroTech and Spine. The company has witnessed tremendous growth over the past few years. It registered strong earnings in fiscal 3Q17 and has exceeded analysts’ estimates for the past several quarters. […]

Myriad Genetics (MYGN) expects to attain a penetration level of 4% in the companion diagnostics segment by 2020.

Myriad Genetics (MYGN) announced the U.S. Food and Drug Administration’s (or FDA) acceptance of its supplementary premarket approval application for BRACAnalysis CDx, a DNA sequencing companion diagnostic test.

Varian’s Oncology segment sales in the Americas rose 2%, whereas order growth in the region rose 1% in 4Q17.

BAX stock plummeted in late 2016 but has witnessed a rise in recent months, trading at a 52-week high on October 27, 2017.

On November 14, 2017, Baxter International (BAX) announced a voluntary recall of one lot of its Nexterone 150 mg/100 mL Premixed Injection.

Overview BD (BDX) has registered strong operating margin expansion in recent years. Its margin improved by 100 basis points in fiscal 2015 and 200 basis points in fiscal 2016. In fiscal 2017, BD’s margin expanded by ~180 basis points. In 4Q17, BD’s operating margin grew ~14.6% YoY (year-over-year), limited by 700 basis points due to the divestiture of BD’s […]

On October 3, 2017, Abbott announced the completion of its acquisition of Alere, which has had troubles since the initial announcement in February 2016.

Abbott (ABT) registered sales growth of ~5% in its Diagnostics business in 3Q17. The segment’s sales were driven by a strong performance outside the US.

Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.

As of October 27, six (~35%) analysts provided a “buy” rating on the BAX stock, while ten (59%) rated the stock a “hold.”

Baxter International’s sales growth guidance for fiscal 2017 is expected to be ~4% on a reported basis.

Analysts’ recommendations on Stryker Stryker (SYK) announced its 3Q17 earnings results on October 26, 2017. In this article, we’ll look at analysts’ ratings, recommendations, and target prices for Stryker over the next 12 months. As of October 30, 2017, of 28 investment research companies surveyed by Reuters, 17 (61%) recommended “buy” for Stryker, nine recommended “hold,” and two recommended […]

Deal overview On October 24, 2017, Stryker (SYK) acquired the majority share capital of Vexim. The acquisition of a controlling stake in Vexim has provided Stryker with an expanded portfolio of minimally invasive technologies. SYK stock fell ~0.15% that day. The Vanguard S&P 500 ETF (VOO), which has a ~0.22% exposure to Stryker, fell ~0.23%. Following the […]

BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.

Johnson & Johnson (JNJ) registered revenues of $18.8 billion, a YoY (year-over-year) increase of around 1.6% in 2Q17.

In 3Q17, the Established Pharmaceuticals segment of Abbott Laboratories is expected to report high double-digit operational sales growth.

The 3Q17 EPS estimate for Abbott Laboratories is $0.65. The company has provided an EPS guidance range of $0.64–$0.66 for 3Q17.

BD has a strong product pipeline of innovative products under development in its LifeSciences segment, which includes the company’s diagnostic offerings.

BD has a 50-day moving average of $197.25, while its 200-day moving average is $192.35.

Thermo Fisher Scientific’s Applied Biosystems DNA Kit (or Yfiler Plus PCR Amplification Kit) generates a CODIS (Combined DNA Index System) database.

Becton Dickinson (BDX), or BD, acquired the global safety products portfolio through the acquisition of CareFusion in 2015.

Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.

Abbott Laboratories (ABT) released its 2Q17 earnings results on July 20, 2017, reporting strong results for revenues as well as earnings and exceeding Wall Street’s estimates.

Baxter International (BAX) has updated its sales guidance growth from 2.0%–3.0% to approximately 4.0% on a constant currency basis.

On September 7, 2017, BAX stock closed at $62.84 per share. It has a 50-day moving average of $61.15 and a 200-day moving average of $57.14.

On August 31, Stryker (SYK) closed trading at a closing price of $139.3. It has a 50-day moving average of $144.7 and a 200-day moving average of $137.5.

Of the 29 brokerage firms tracking Zimmer Biomet, 18 (62%) analysts gave ZBH stock a “buy” rating, while nine (~31%) provided a “hold” rating.

Becton Dickinson (BDX) expects to register a strong performance in the last quarter of fiscal 2017 and thus register a robust 2017 performance.

Becton Dickinson (BDX) has seen tremendous growth in recent years, driven by some of its major acquisitions and key product launches.

Becton Dickinson’s (BDX) emerging markets registered a strong double-digit growth of 10.9% in 3Q17.